Metraipolis › archive › dc_ab298cdefb89

Cost-effectiveness of pirfenidone for patients with cancer and grade 2 or grade 3 radiation-induced lung injury: A modeling study — Europe PMC PMID:42555672

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42555672
DOI
10.1371/journal.pmed.1004817
License (as archived)
solo-consultazione
Archived
2026-10-08T00:49:58.608Z
SHA-256 of the archived text
6df15430248b58b13f30f7fe39ec6ca49985d1113d497339acb510ec5fce0e61
Stable URL of this page
https://metraipolis.com/documento/dc_ab298cdefb89

How to cite

Cost-effectiveness of pirfenidone for patients with cancer and grade 2 or grade 3 radiation-induced lung injury: A modeling study — Europe PMC PMID:42555672 — Europe PMC (en), https://europepmc.org/article/MED/42555672 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ab298cdefb89 (Metraipolis archive dc_ab298cdefb89, sha256 6df15430248b58b13f30f7fe39ec6ca49985d1113d497339acb510ec5fce0e61)
BibTeX
@misc{dcab298cdefb89,
  title = {Cost-effectiveness of pirfenidone for patients with cancer and grade 2 or grade 3 radiation-induced lung injury: A modeling study — Europe PMC PMID:42555672},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42555672},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ab298cdefb89; sha256 6df15430248b58b13f30f7fe39ec6ca49985d1113d497339acb510ec5fce0e61},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42555672. Agents can read the archived copy with the MCP tool read_document.